Samil Pharm: Q1 2026 Consolidated Operating Loss of 8.4B KRW, Continuing Losses and Rising Debt Ratio

Consolidated revenue: 52.5B KRW (vs. 52.3B in prior-year period, slight increase)
Consolidated operating loss: 8.4B KRW (loss continues, widened YoY)
Consolidated net loss: 10.8B KRW
Consolidated net debt-to-equity ratio: 126.6% (up from 116.8% at year-end)
Separate operating loss: 1.9B KRW (due to recall costs for Seonglikotai)
Consolidated retained earnings: -27.2B KRW (worsened from -16.3B)
R&D expenses: 1.54B KRW (2.93% of sales)
Treasury shares disposal: 141,000 shares (increase in capital surplus)
Two pending lawsuits (no provision recognized)